BiotechTube

Rocuronium (moderate NMB) + Rocuronium (deep NMB)

Pre-clinicalUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuromuscular Block

Conditions

Neuromuscular Block, Surgery

Trial Timeline

May 1, 2019 → Dec 1, 2019

NCT ID
NCT03287388

About Rocuronium (moderate NMB) + Rocuronium (deep NMB)

Rocuronium (moderate NMB) + Rocuronium (deep NMB) is a pre-clinical stage product being developed by Merck for Neuromuscular Block. The current trial status is unknown. This product is registered under clinical trial identifier NCT03287388. Target conditions include Neuromuscular Block, Surgery.

What happened to similar drugs?

15 of 20 similar drugs in Neuromuscular Block were approved

Approved (15) Terminated (2) Active (5)
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
✅Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
✅neostigmine/glycopyrrolate + sugammadexMerckApproved
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
✅Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved

Hype Score Breakdown

Clinical
3
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03287388Pre-clinicalUNKNOWN

Competing Products

20 competing products in Neuromuscular Block

See all competitors
ProductCompanyStageHype Score
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
35
Placebo + Sugammadex + Esmeron®MerckPhase 2
35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
43
Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
39
Rocuronium + Succinylcholine + Cisatracurium + Mivacurium + Sugammadex + NeostigmineMerckPre-clinical
26
Sugammadex + RocuroniumMerckApproved
43
sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
43
neostigmine/glycopyrrolate + sugammadexMerckApproved
43
sugammadexMerckPhase 3
40
2 mg/kg sugammadex + 0.07 mg/kg neostigmineMerckPhase 3
47
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
43
Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved
35
Sugammadex + NeostigmineMerckApproved
43
Sugammadex 2 mg/kg ABW + Sugammadex 2 mg/kg IBW + Sugammadex 4 mg/kg ABW + Sugammadex 4 mg/kg IBW + Neostigmine + Glycopyrrolate + Rocuronium or VecuroniumMerckApproved
43
sugammadex + Neostigmine + GlycopyrrolateMerckApproved
43
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline + Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;MerckPhase 2
35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
43
Rocuronium Bromide + Rocuronium BromideMerckApproved
43